HuaRen Bio Secures RMB 100 Million Series A Financing to Advance Clinical Development and Key Pipeline Programs

Recently,Beijing B&K Biotechnology Co., Ltd., a biopharmaceutical R&D enterprise(hereinafter referred to as“B&K CORPORATION”) announced the successful completion of100 million yuanAround of financing. This round of financingExclusively invested by CDH Investments. China Renaissance Capital served as theB&K CORPORATIONexclusive financial advisor.

This round of financing will be primarily used to advance the Phase II clinical trials of B&K CORPORATION’s platelet-derived growth factor TPG project in China and the United States, as well as to support the R&D of multiple other blockbuster pipelines, including mRNA vaccines.

Beijing B&K Biotechnology Co., Ltd., established in 2012, is a national high-tech enterprise primarily engaged in the research and development of biologic drugs. Leveraging extensive expertise in cutting-edge biologics, vaccines, and nanocapsule delivery systems, its R&D team develops biologic drugs and vaccines that address significant unmet clinical needs. The company’s novel TPG gel formulation, with diabetic foot ulcers as its first indication, was jointly developed by the Academy of Military Sciences’ Institute of Military Medicine and Beijing B&K Biotechnology Co., Ltd., and is currently undergoing Phase I clinical trials.

Wei Bin, Senior Partner at CDH Investments, stated, “B&K CORPORATION boasts significant advantages in the R&D of biomacromolecule drugs and vaccines, as well as in the development of delivery systems, thanks to its interdisciplinary R&D team. The combined application of its multiple technology platforms is expected to yield a robust pipeline of blockbuster products. We are delighted to partner with innovative enterprises like B&K CORPORATION.”

Beijing B&K Biotechnology Co., Ltd., established in 2012, is a national high-tech enterprise primarily engaged in the research and development of biologic macromolecule drugs. B&K CORPORATION boasts a robust R&D team, with its leaders possessing extensive experience in molecular biology, innovative drug discovery, and vaccine development; more than 80% of the R&D staff hold master’s or doctoral degrees. Currently, the company’s platelet-derived growth factor (TPG) project has received clinical trial approval from the National Medical Products Administration (NMPA) for its first indication, and Phase I clinical studies are underway.

B&K CORPORATION continues to deepen its collaborations with top global research institutions and has established multiple technology platforms, including a yeast expression platform, an mRNA platform, and a nanocapsule delivery system. In the future, the company will rapidly advance simultaneous regulatory filings in China and the United States, as well as clinical studies, for multiple self-developed product pipelines, including TPG and mRNA vaccines.

CDH Investments, established in 2002, is one of China’s most influential alternative asset management firms, with assets under management exceeding RMB 170 billion. The firm has invested in more than 240 companies, over 70 of which are listed on domestic and international stock exchanges, fostering a cohort of industry-leading brands. The portfolio companies of CDH Investments employ more than 1.5 million people, serving as a significant driver of economic vitality in China.

China Renaissance is a leading new-economy investment bank in China, focusing on the global TMT, consumer, and healthcare sectors. In addition to its investment banking services, China Renaissance manages one RMB-denominated fund and one USD-denominated fund. The firm has offices in Beijing, Shanghai, Los Angeles, and San Francisco, and holds licenses to operate in the U.S. securities markets. Healthcare is a key focus area where China Renaissance possesses deep expertise and competitive advantages. Moreover, China Renaissance boasts the largest, most professional, and most comprehensively integrated healthcare investment banking team in China.